Increases in rates as well as morbidity and mortality associated with fungal infections have necessitated the need for additional antifungal agents. Recent research has resulted in the introduction of 3 new antifungal agents: micafungin, anidulafungin, and posaconazole. Micafungin and anidulafungin, both potent inhibitor of 1,3-β-D-glucan synthase, are the second and third available agents in the echinocandins class that are available in clinical practice. Posaconazale, a potent inhibitor of ergosterol synthesis, is a new agent in the triazole class that has shown promising clinical efficacy in the treatment and prophylaxis of invasive fungal infections due to Candida as well as molds. This article reviews the clinical efficacy as well as the approved uses and dosages associated with the use of these new antifungal agents. Other considerations, such as precautions, administration techniques, potential drug interactions, and common adverse effects associated with the use of these agents, are also reviewed.
Skip Nav Destination
Article navigation
1 July 2007
Features|
July 01 2007
Update on New Antifungal Therapy
Paul Juang, PharmD, BCPS
Paul Juang, PharmD, BCPS
Paul Juang is Assistant Professor of Pharmacy Practice in the Department of Pharmacy Practice, St Louis College of Pharmacy, 4588 Parkview Place, St Louis, MO 63110 ([email protected]).
Search for other works by this author on:
AACN Adv Crit Care (2007) 18 (3): 253–260.
Citation
Paul Juang; Update on New Antifungal Therapy. AACN Adv Crit Care 1 July 2007; 18 (3): 253–260. doi: https://doi.org/10.4037/15597768-2007-3004
Download citation file:
Sign in
Don't already have an account? Register
Short-term Access
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access